Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

Bladder cancer is a serious disease that begins in the lining of the bladder, the organ that stores urine. When the cancer ...

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...

It is used both to treat tumours and to help clinicians determine whether they are cancerous, as well as their grade and ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

CEO Richard Adcock said physicians could prescribe Anktiva for papillary bladder cancer if it is added to NCCN treatment guidelines. ・The company recently filed a supplemental biologics license ...

An aggressive bladder cancer diagnosis made 2025 one of the toughest years of Deion Sanders’ life. Coach Prime underwent a ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

For years, Susan Johnstone, 53, lived with an embarrassing problem that threatened to take away the activity she loved most: ...

Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted ...

Lili Reinhart opened up about how fearful she was that infertility was a possibility before she was diagnosed with ...